Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NBE-002
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Cmed Clinical Services
Deal Size : Inapplicable
Deal Type : Inapplicable
NBE-002 in Patients With Advanced Solid Tumors
Details : NBE-002 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
June 22, 2020
Lead Product(s) : NBE-002
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Cmed Clinical Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
